Viktor Drvota
Chief Executive Officer bij KAROLINSKA DEVELOPMENT AB
Oorsprong van het eerstegraads netwerk van Viktor Drvota
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Financial Conglomerates | 29 | |
Karolinska Institutet
24
| College/University | Other Consumer Services | 24 |
23
| Public Company | Medical Specialties | 23 |
SEB Venture Capital
 SEB Venture Capital Investment ManagersFinance SEB Venture Capital (SEB Venture Capital) is a venture capital subsidiary of Skandinaviska Enskilda Banken AB founded in 1995. The firm is headquartered in Stockholm, Sweden.
17
| Operating Division | Investment Managers | 17 |
Dilafor AB
 Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland.
9
| Subsidiary | Pharmaceuticals: Major | 9 |
| Public Company | Medical Specialties | 8 | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
7
| Operating Division | Investment Managers | 7 |
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden.
7
| Holding Company | Pharmaceuticals: Major | 7 |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
Svenska Vaccinfabriken Produktion AB
 Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022.
6
| Holding Company | Biotechnology | 6 |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
| Public Company | Biotechnology | 4 | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden.
3
| Subsidiary | Biotechnology | 3 |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Dilafor Incentive AB
1
| Private Company | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Viktor Drvota via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| HYPERION THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| MEDIVIR AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Royal Swedish Academy of Sciences
 Royal Swedish Academy of Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Sciences provides research and development services on sciences. The non-profit company is based in Stockholm, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| SINO BIOPHARMACEUTICAL LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal Chairman Corporate Officer/Principal | |
| OREXO AB | Pharmaceuticals: Major | Director of Finance/CFO Director of Finance/CFO | |
| University of London | College/University | Graduate Degree Doctorate Degree Doctorate Degree | |
| Stockholm School of Economics | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree Graduate Degree Masters Business Admin | |
| University of Uppsala | College/University | Lena Birgitta Degling Wikingsson | Masters Business Admin Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree Graduate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree |
ApaTech Ltd.
 ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Medical Specialties | Chief Executive Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer Founder | |
| ABLYNX | Biotechnology | Chairman Director/Board Member | |
| SCIBASE HOLDING AB (PUBL) | Medical Specialties | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
| Royal Institute of Technology | College/University | Doctorate Degree Graduate Degree Graduate Degree | |
| University of Lund | College/University | Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
| VIVESTO AB | Pharmaceuticals: Generic | Director of Finance/CFO Chairman | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chief Administrative Officer | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
Rhenman & Partners Asset Management AB
 Rhenman & Partners Asset Management AB Investment ManagersFinance Rhenman & Partners Asset Management AB (Rhenman & Partners) is an independent Swedish alternative investment management firm which was founded in 2008 by a group of senior asset management industry executives including Henrik Rhenman and Göran Nordström. Headquartered in Stockholm, the firm is exclusively focused on the healthcare sector and manages the Rhenman Healthcare Equity L/S Fund, supported by a Scientific Advisory Board with a network of scientists and experts at renowned scientific institutions, including the Karolinska Institute and the University of Uppsala. | Investment Managers | Chairman Analyst-Equity | |
GlaxoSmithkline AB
 GlaxoSmithkline AB Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AB is a Swedish pharmaceutical company that manufactures pharmaceutical products. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| KCIF Fund Management AB | Director/Board Member Chairman Director/Board Member | ||
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Reapplix A/S
 Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | Medical Distributors | Director/Board Member Director/Board Member | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer Chief Tech/Sci/R&D Officer | |
NovaSAID AB
 NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Comptroller/Controller/Auditor Chairman | |
ENCare AB
 ENCare AB Packaged SoftwareTechnology Services ENCare AB provides interactive and web-based information system for healthcare industry. It offers an interface for the collection, documentation, and feedback of performance from clinical experts. The company was founded by Olle Harald Ljungqvist and Knut Ivar Magnus Stafsing in 2009 and is headquartered in Stockholm, Sweden. | Packaged Software | Chairman Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
Karolinska University Hospital
 Karolinska University Hospital Hospital/Nursing ManagementHealth Services Karolinska University Hospital is a premier health facility and one of Europe's largest teaching hospitals located in Stockholm, Sweden. The Swedish company provides healthcare services for a wide range of disorders, from major public health diseases to rare medical conditions. As a designated provider of highly specialized medical services, they have a primary responsibility for the clinical components of research and education. Together with the world-respected Karolinska Institutet, they lead in medical breakthroughs. The company educates and train tomorrow's medical specialists and healthcare professionals as a major teaching hospital. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Biomatcell AB
 Biomatcell AB BiotechnologyHealth Technology Biomatcell AB operates as a holding company that commercializes inventions in the fields of biomaterial science and cell therapy by licensing its inventions and creating spin-off companies. It develops three-dimensional biomaterial scaffold geometries in bioactive ceramics and metals. It markets products and services based on research in the field of biomaterials and stem cells and patenting new ideas in the same area. The company was founded on May 11, 2004 and is headquartered in Gothenburg, Sweden. | Biotechnology | Director/Board Member Director/Board Member | |
Palette Life Sciences AB
 Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member Founder Director of Finance/CFO | |
| KD Incentive AB | Director/Board Member Director/Board Member Director/Board Member | ||
| VALNEVA | Biotechnology | Director/Board Member Director/Board Member | |
Asceneuron SA
 Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Scibase AB | Chief Executive Officer Director/Board Member Corporate Officer/Principal | ||
Mimir Capital AB
 Mimir Capital AB Investment ManagersFinance Mimir Capital AB (Mimir Capital) is a private equity firm founded in 2013. The firm is headquartered in Stockholm, Sweden. | Investment Managers | Chairman Chief Executive Officer | |
Softhale NV
 Softhale NV Miscellaneous Commercial ServicesCommercial Services Softhale NV engages in manufacturing medical, clinical and pharmaceutical equipment. The company was founded by Jurgen Rawert and Frank Bartels and is headquartered in Diepenbeek, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| ANNEXIN PHARMACEUTICALS AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
ReWind Therapeutics NV
 ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| BIOSERGEN AB | Biotechnology | Chairman Director/Board Member | |
AnaCardio AB
 AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
invoX Pharma Ltd.
 invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The private company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Investment Officer | |
| Recion Oy | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Zweden | 33 |
| Verenigd Koninkrijk | 5 |
| Verenigde Staten | 4 |
| België | 4 |
| Denemarken | 4 |
Sectoraal
| Health Technology | 28 |
| Consumer Services | 8 |
| Commercial Services | 7 |
| Finance | 3 |
| Distribution Services | 2 |
Operationeel
| Director/Board Member | 494 |
| Corporate Officer/Principal | 202 |
| Chairman | 120 |
| Chief Executive Officer | 103 |
| Independent Dir/Board Member | 68 |
Sterkste connecties
- Beurs
- Insiders
- Viktor Drvota
- Bedrijfsconnecties
